Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Q4 Revenues Slide 35 Percent as Profit Turns to Loss

NEW YORK, Feb. 17 (GenomeWeb News) - Ciphergen yesterday reported that its fourth-quarter sales fell 35 percent to $6.6 million from $10.1 million during the year-ago period, as net income fell into the red.

 

Research and development costs fell to $3 million from $3.7 million a year ago.

 

Ciphergen reported a net loss of $9.2 million, or $0.26 per share, versus a net income of $10.3 million, or $0.35, in the fourth quarter of 2004. The company said the results included a $2.5-million non-cash charge for the impairment of goodwill.

 

As of Dec. 31, the company had $25.7 million in cash and cash equivalents.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.